Can Human Growth Hormone Be Genericized?
Executive Summary
Genentech solidified its grip on the $350 million US market for human growth hormone through aggressive marketing, creative value-added services, and savvy timing. But a crop of new competitors, waiting for FDA approval of their nearly identical versions of the drug, are likely to change the basis of competition and most importantly, make pricing an issue.
You may also be interested in...
Biogenerics Are Coming and They're Not the Generics We Know
Biotech and would-be biogenerics companies are battling to shape the future of generic biologics. The FDA, along with established biotech and drug companies, has opposed the concept of biogenerics, insisting the compounds are too complex to be reproducible in a reliable fashion. Challengers insist that the science is advanced enough to make such products feasible and are pumping significant time and money into bringing them to market.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”